Share information
213.50 €
+0.66 %
22/09/2026 17:36
+0.66 %
Open
High
Low
Volume
212.10 €
213.50 €
207.90 €
227,356
Latest News
09-Sep-2026
UCB receives U.S. FDA Breakthrough Therapy Designation for CIMZIA[®] (certolizumab pegol) in pregnant women with antiphospholipid syndrome (APS)
08-Sep-2026
UCB opens ‘Expressing Epilepsy’ art exhibition featuring acclaimed artists living with epilepsy
01-Sep-2026
UCB presents data at EEC 2026 highlighting continued leadership in epilepsy and developmental and epileptic encephalopathies
31-Aug-2026
Transparency notification Wellington Management Group LLP